We are live on !
Find out more
Red Tree Management Portfolio holdings
AUM
$117M
Turnover
0%
1-Year Est. Return
89.68%
This Fund
S&P 500
This Quarter Est. Return
-7%
1 Year Est. Return
+89.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
-$30.6M
(-21%)
Cap. Flow
-$6.08M
Cap. Flow % of AUM
Cap. Flow %
-5.21%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
1.8
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bicara Therapeutics
BCAX
|
+$6.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Bicara Therapeutics
BCAX
$644M
| $54.4M | 46.57% |
2,920,509
-243,008
| -8% | -$6.08M |
2024 Q4
7 quarters
|
|
2
CeriBell Inc
CBLL
$1.07B
| $53.8M | 46.09% |
2,205,661
| – | – |
2024 Q4
7 quarters
|
|
3
Contineum Therapeutics
CTNM
$351M
| $8.56M | 7.34% |
638,158
| – | – |
2024 Q4
7 quarters
|
|
Similar funds
EP
Red Tree Management's Q3 2026 Portfolio in Review
As of Q3 2026, Red Tree Management held 3 positions worth $117M, down 21% from $147M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Red Tree Management withdrew a net $6.08M in Q3 2026, reducing 1 holding. Its largest reduction was Bicara Therapeutics, cutting an estimated $6.08M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Red Tree Management's biggest Q3 2026 reduction was Bicara Therapeutics, cutting an estimated $6.08M.
- Red Tree Management's ten largest holdings make up 100% of its $117M portfolio in Q3 2026.
- Red Tree Management opened 0 new positions and closed 0 in Q3 2026.
- Red Tree Management's portfolio value fell 21% quarter-over-quarter to $117M.
Based on Red Tree Management's 13F filing for Q3 2026, filed 15 Oct 2026.